io biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of t cells that are specific for immune inhibitory molecules. io biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting ido and pd-l1 in clinical development and several compounds finalizing preclinical phase. io biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
Company profile
Ticker
IOBT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
870909276
IOBT stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
10-K/A
2023 FY
Annual report (amended)
22 Mar 24
S-8
Registration of securities for employees
11 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
5 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
IO Biotech Announces 2023 Third Quarter Results
13 Nov 23
Latest ownership filings
4
Mai-Britt Zocca
18 Mar 24
4
Amy Sullivan
18 Mar 24
4
Devin Whittemore Smith
18 Mar 24
4
Brian Burkavage
18 Mar 24
4
Qasim Iftikhar Ahmad
18 Mar 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13D/A
Novo Holdings A/S
13 Feb 24
4
Change in insider ownership
13 Feb 24
SC 13G/A
BANK OF AMERICA CORP /DE/
13 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 165.77 mm | 165.77 mm | 165.77 mm | 165.77 mm | 165.77 mm | 165.77 mm |
Cash burn (monthly) | (no burn) | (no burn) | 7.83 mm | 6.97 mm | 5.33 mm | 5.12 mm |
Cash used (since last report) | n/a | n/a | 53.66 mm | 47.78 mm | 36.54 mm | 35.11 mm |
Cash remaining | n/a | n/a | 112.11 mm | 117.99 mm | 129.23 mm | 130.66 mm |
Runway (months of cash) | n/a | n/a | 14.3 | 16.9 | 24.2 | 25.5 |
Institutional ownership, Q2 2023
36.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 23.95 bn |
Total shares | 23.73 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lundbeckfond Invest A/S | 6.05 mm | $80.58 mm |
Novo Holdings A/S | 3.28 mm | $6.41 bn |
Vivo Capital | 3.02 mm | $5.90 bn |
Vivo Capital IX | 3.02 mm | $40.17 mm |
HBM Healthcare Investments | 2.42 mm | $15.49 mm |
Avoro Capital Advisors | 2.06 mm | $4.03 bn |
BAC Bank Of America | 1.85 mm | $3.62 bn |
Samsara BioCapital | 1.01 mm | $1.97 bn |
Partner Fund Management | 612.71 k | $1.20 bn |
Bridgeway Capital Management | 132.20 k | $259.11 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Qasim Iftikhar Ahmad | Stock Option Common Stock | Grant | Acquire A | No | No | 1.65 | 280,000 | 462.00 k | 280,000 |
15 Mar 24 | Amy Sullivan | Stock Option Common Stock | Grant | Acquire A | No | No | 1.65 | 280,000 | 462.00 k | 280,000 |
15 Mar 24 | Devin Whittemore Smith | Stock Option Common Stock | Grant | Acquire A | No | No | 1.65 | 185,000 | 305.25 k | 185,000 |
15 Mar 24 | Mai-Britt Zocca | Stock Option Common Stock | Grant | Acquire A | No | No | 1.65 | 750,000 | 1.24 mm | 750,000 |
15 Mar 24 | Brian Burkavage | Stock Option Common Stock | Grant | Acquire A | No | No | 1.65 | 50,000 | 82.50 k | 50,000 |
Press releases
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 Apr 24
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
15 Apr 24
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
9 Apr 24
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
5 Apr 24
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
6 Mar 24